Frequency of Lp(a) elevation and hereditary risk factors of VTE and risk of VTE (univariate analysis)
| Risk factor . | Patients, n (%) . | Controls, n (%) . | Pvalues χ2 test* . | OR (95% CI) . |
|---|---|---|---|---|
| Lp(a) > 30 mg/dL | 135/685 (20) | 19/266 (7) | <.001 | 3.2 (1.9-5.3) |
| FV G1961A heterozygous | 205/683 (29) | 19/256 (7) | <.001 | 5.7 (3.5-9.3) |
| FV G1961A homozygous | 26/683 (4) | 0/256 (0) | — | — |
| Prothrombin G20210A | 45/664 (7) | 6/235 (2.6) | .03 | 2.8 (1.2-6.6) |
| MTHFR 677TT† | 49/486 (10) | 22/161 (14) | .2 | 0.7 (0.4-1.2) |
| Protein C deficiency | 15/611 (3) | 3/228 (1) | .46 | 1.8 (0.5-6.6) |
| Protein S deficiency | 24/612 (4) | 5/219 (2) | .33 | 1.8 (0.7-4.7) |
| Antithrombin deficiency | 17/685 (2.5) | 1/226 (0.4) | 0.1 | 5.7 (0.8-43.3) |
| Lp(a) and FV G1691A‡ | 49/683 (7) | 2/256 (0.8) | <.001 | 9.8 (2.4-40.7) |
| Risk factor . | Patients, n (%) . | Controls, n (%) . | Pvalues χ2 test* . | OR (95% CI) . |
|---|---|---|---|---|
| Lp(a) > 30 mg/dL | 135/685 (20) | 19/266 (7) | <.001 | 3.2 (1.9-5.3) |
| FV G1961A heterozygous | 205/683 (29) | 19/256 (7) | <.001 | 5.7 (3.5-9.3) |
| FV G1961A homozygous | 26/683 (4) | 0/256 (0) | — | — |
| Prothrombin G20210A | 45/664 (7) | 6/235 (2.6) | .03 | 2.8 (1.2-6.6) |
| MTHFR 677TT† | 49/486 (10) | 22/161 (14) | .2 | 0.7 (0.4-1.2) |
| Protein C deficiency | 15/611 (3) | 3/228 (1) | .46 | 1.8 (0.5-6.6) |
| Protein S deficiency | 24/612 (4) | 5/219 (2) | .33 | 1.8 (0.7-4.7) |
| Antithrombin deficiency | 17/685 (2.5) | 1/226 (0.4) | 0.1 | 5.7 (0.8-43.3) |
| Lp(a) and FV G1691A‡ | 49/683 (7) | 2/256 (0.8) | <.001 | 9.8 (2.4-40.7) |